Protein for muscle vs protein for longevity — the mTOR-IGF-1 tension

Protein builds muscle. Protein activates mTOR. mTOR inhibition extends life in mice. Follow that chain and you reach one of the sharpest tensions in longevity medicine: the same dietary lever that preserves muscle mass may, in some people, accelerate aging through a pathway that rapamycin suppresses. Neither camp is wrong. Neither camp has the full picture.

What the primary literature shows

On the muscle side, the evidence is solid. A 2018 meta-analysis found that muscle protein synthesis plateaus at roughly 1.6 g/kg of body weight per day when combined with resistance training [1]. Grip strength and lean mass, the downstream products of adequate protein intake, predict survival across large prospective cohorts [2]. No documented harm has appeared at intakes up to 3.2-4.5 g/kg for up to one year, though this safety range comes from analyst synthesis of athlete studies rather than primary longevity trials [3].

On the longevity side, Levine et al. found that midlife adults in the highest protein quartile had roughly 75% higher all-cause mortality and approximately four times the cancer mortality over 18 years, with improved IGF-1 identified as the likely mediator [4]. That number gets cited often. It also gets stripped of context as often.

The critical modifiers the headlines drop

Two features of the Levine data change the interpretation substantially. First, the improved mortality concentrated in sedentary adults with other unhealthy lifestyle factors. Verhoeven's analysis suggests that when physically active individuals without obesity, smoking, or heavy alcohol use are separated from that cohort, the association disappears [5]. Second, the relationship reversed in adults over 65, where higher protein became protective. Reading the four-times cancer finding as a blanket warning about dietary protein ignores both patterns.

Verhoeven's analysis also points to a Longo-group U-curve for IGF-1: both chronically improved and chronically suppressed IGF-1 correlate with higher mortality, with an estimated best range of 120-160 ng/mL [3]. That range is thought to correspond to roughly 50-80 g/day of total protein for most adults, pending verification of the underlying meta-analysis [3]. The practical implication is that extreme protein restriction carries its own risk. The longevity concern is chronic IGF-1 elevation, not meeting a minimum adequate intake.

Exercise as the reconciling variable

Physical activity appears to redirect IGF-1 and leucine signaling toward muscle repair and neurogenesis, pulling them away from peripheral tissue where chronically improved IGF-1 and mTOR may support pre-cancerous cells. Exercise also raises IGF-1 binding proteins, which modulates free IGF-1 availability.

Verhoeven's analysis suggests that in the 24 hours after exercise, protein intake does not produce the IGF-1 rise seen with equivalent protein consumed without prior physical activity. The specific study underlying this claim has not yet been located in the source literature [3]. Separately, Verhoeven's reading of athlete cohort data suggests that populations eating more protein, running higher IGF-1, and training consistently show longer life expectancy with lower rates of cancer and cardiovascular disease [5]. Neither claim should stand as settled; the primary citations remain pending identification.

Peter Attia's position frames the issue as context-dependent mTOR activation. It is expert opinion, not a research finding. Acute mTOR signaling in skeletal muscle after exercise is the desired state; chronic systemic activation without a metabolic "job" is the concern [5].

Where experts disagree on how much protein to eat

Even within the muscle-focused camp, there is no consensus on a daily target. Stuart Phillips, whose lab produced the 1.6 g/kg saturation data [1], recommends that figure as a practical ceiling for most people [6]. Attia recommends 2.0 g/kg as a floor heuristic, reasoning that targeting higher protects against days when intake falls short [5]. Gabrielle Lyon recommends 2.2 g/kg (approximately 1 g/lb), a muscle-maximalist position that exceeds the documented MPS plateau in the primary literature [7]. Lyon's guidance should be read with awareness that her clinical practice and brand center on high-protein protocols, which constitutes a conflict of interest.

None of these figures is a LampHill recommendation. They are what these clinicians advise and why.

Two compounding risks

Rapamycin inhibits mTORC1 and blunts muscle protein synthesis as a known side effect. If mTOR inhibition is the mechanism of life extension and muscle mass is itself protective, anyone taking rapamycin faces a direct internal tension that requires active muscle monitoring [5].

GLP-1 receptor agonists create a second compounding risk. Lyon argues that anabolic resistance in aging makes the leucine threshold at each meal, not total daily protein, the critical variable [7]. GLP-1-driven appetite suppression may push protein per meal below that threshold without affecting total calorie restriction goals. Attia addresses this in tirzepatide patients with DEXA monitoring and liquid protein supplementation [5].

Where the evidence is contested

The Levine 2014 mortality data [4] are genuine primary literature, but their interpretation remains disputed. Longo and CR-aligned researchers read them as evidence that high animal protein in midlife raises cancer and mortality risk through IGF-1. Phillips-aligned researchers and Verhoeven's synthesis [5] read the same data differently. To them, the finding is specific to sedentary, metabolically unhealthy adults. The association disappears in active people and reverses after 65. Both readings engage honestly with the same dataset. They weight the subgroup analyses differently.

The U-curve for IGF-1 [3] matters analytically, but it rests on a meta-analysis ([8]) whose PMID has not yet been confirmed in LampHill's source system. The exercise-IGF-1 interaction claim also cites a study not yet fully located. These remain pending verification, not fabrications. They should not be cited as settled evidence until primary sources are confirmed.

References

1. Morton et al. 2018, BJSM — protein + RT meta (1.6 g/kg) · PubMed 28698222
2. Leong et al. 2015, Lancet (PURE) — grip strength & mortality · PubMed 25982160
3. FMF — Rhonda Patrick solo: protein, longevity, cancer, aging, muscle
4. Levine et al. 2014, Cell Metab — protein, IGF-1 & mortality · PubMed 24606898
5. Attia ep369 — Protein needs + muscle for longevity (Attia + Patrick)
6. FMF — Rhonda Patrick + Stuart Phillips: protein + muscle
7. Huberman — Gabrielle Lyon: muscle-centric medicine + longevity
8. Rahmani et al. 2022 (Aging Cell) — Longo meta-analysis; 19 studies, 30,876 subjects; U-shaped IGF-1/mortality; optimal ~120–160 ng/mL ≈ ~50–80… · PubMed 35048526